{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e8308ce6b0fef1a38c4a215/6a06e978a8fad4c1be0a72a0?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML? ","description":"<p>The AML Hub was pleased to speak with Joshua Zeidner, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML? </p><p><br></p><p>Zeidner provides an overview of currently approved menin inhibitors and discusses combination strategies in development for the treatment of NPM1-mutated (NPM1m) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML). He highlights key data from ongoing trials of menin inhibitor combination approaches, which aim to improve outcomes in both newly diagnosed (ND) and relapsed/refractory (R/R) patient populations. </p><p><br></p><p>This educational resource is independently supported Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.</p>","author_name":"Scientific Education Support"}